Both in Biotechnology
Denali Therapeutics vs ADMA Biologics
Over the past year DNLI returned +38.3% and ADMA returned −27.6%; their daily moves had a correlation of 0.25.
DNLI +38.3% ADMA −27.6%Growth of $1, one year, split-adjusted
| Metric | DNLI | ADMA |
|---|---|---|
| Price | $19.45 | $11.11 |
| Market cap | $3.11B | $2.49B |
| Today | +3.13% | +0.45% |
| 1 month | −2.3% | +9.9% |
| 6 months | +2.8% | +8.4% |
| Year to date | +17.8% | −39.1% |
| 1 year | +19.5% | −28.2% |
| Revenue growth (YoY) | — | +2.0% |
| Gross margin | 97.4% | 69.4% |
| Net margin | −3539.2% | 30.4% |
| P/E (TTM) | — | 14.7× |
| Price / sales | 862.7× | 4.9× |
| Net cash | $705.0M | -$60.6M |
| Dividend yield | — | — |
| Volatility (60d) | 38.0% | 38.5% |
| Short % of float | 11.6% | 9.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).